Author:
Ansari Mohammad Javed,Alnakhli Mohammed,Al-Otaibi Turki,Meanazel Osaid Al,Anwer Md Khalid,Ahmed Mohammed Muqtader,Alshahrani Saad M.,Alshetaili Abdullah,Aldawsari Mohammed F.,Alalaiwe Ahmad S.,Alanazi Ahmed Z.,Zahrani Mohammed A.,Ahmad Niyaz
Funder
Prince Sattam bin Abdulaziz University
Reference126 articles.
1. Discovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinase;Huang;J. Med. Chem.,2016
2. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial;Kim;J. Clin. Oncol.,2017
3. Brigatinib: first global approval;Markham;Drugs,2017
4. The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis;Hou;Canc. Manag. Res.,2019
5. Safety issues with the ALK inhibitors in the treatment of NSCLC: a systematic review;Kassem;Crit. Rev. Oncol. Hematol.,2018
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献